Indevus/Pliva Co-Promotion Deal Puts 481 Reps Behind Incontinence Drug Sanctura
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanctura (trospium) is currently pending at FDA with a May 28 user fee goal date. Indevus' overactive bladder treatment will face competition from upcoming agents by marketing heavyweights Novartis (Enablex) and GlaxoSmithKline/Yamanouchi (Vesicare); both are "approvable" at FDA.
You may also be interested in...
Pliva Divests Sanctura, Cites Lack Of Resources To Support The Incontinence Agent
The overactive bladder therapy is the first product to be divested as part of a strategic realignment under which Pliva will exit the brand business. The company says brand products are not meeting expectations, and the resources needed are higher than once expected.
Pliva Divests Sanctura, Cites Lack Of Resources To Support The Incontinence Agent
The overactive bladder therapy is the first product to be divested as part of a strategic realignment under which Pliva will exit the brand business. The company says brand products are not meeting expectations, and the resources needed are higher than once expected.
Indevus To Price Sanctura At 10% Discount To Pfizer Detrol LA
A daily dose of Sanctura – two 20 mg tablets – will carry an average wholesale price of $2.98. Retail pharmacies will begin receiving initial shipments of the incontinence agent over the next week, Indevus said.